Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
Calliditas provides setanaxib patent update
Contributed by:
PR Newswire
Tags
Calliditas-Announce
More Like This
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
Calliditas provides patent update
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
